Apoptotic Membrane Blebbing Is Regulated by Myosin Light Chain Phosphorylation by Mills, Jason C. et al.
 
ã
 
 The Rockefeller University Press, 0021-9525/98/02/627/10 $2.00
The Journal of Cell Biology, Volume 140, Number 3, February 9, 1998 627–636
http://www.jcb.org 627
 
Apoptotic Membrane Blebbing Is Regulated
by Myosin Light Chain Phosphorylation
 
Jason C. Mills, Nicole L. Stone, Joseph Erhardt, and Randall N. Pittman
 
Department of Pharmacology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104
 
Abstract. 
 
The evolutionarily conserved execution 
phase of apoptosis is defined by characteristic changes 
occurring during the final stages of death; specifically 
cell shrinkage, dynamic membrane blebbing, condensa-
tion of chromatin, and DNA fragmentation. Mecha-
nisms underlying these hallmark features of apoptosis 
have previously been elusive, largely because the exe-
cution phase is a rapid event whose onset is asynchro-
nous across a population of cells. In the present study, a 
model system is described for using the caspase inhibi-
tor, z-VAD-FMK, to block apoptosis and generate a 
synchronous population of cells actively extruding and 
retracting membrane blebs. This model system allowed 
us to determine signaling mechanisms underlying this 
characteristic feature of apoptosis. A screen of kinase 
inhibitors performed on synchronized blebbing cells in-
dicated that only myosin light chain kinase (MLCK) in-
hibitors decreased blebbing. Immunoprecipitation of 
myosin II demonstrated that myosin regulatory light 
chain (MLC) phosphorylation was increased in 
blebbing cells and that MLC phosphorylation was pre-
vented by inhibitors of MLCK. MLC phosphorylation 
is also mediated by the small G protein, Rho. C3 trans-
ferase inhibited apoptotic membrane blebbing, sup-
porting a role for a Rho family member in this process. 
Finally, blebbing was also inhibited by disruption of the 
actin cytoskeleton. Based on these results, a working 
model is proposed for how actin/myosin II interactions 
cause cell contraction and membrane blebbing. Our re-
sults provide the first evidence that MLC phosphoryla-
tion is critical for apoptotic membrane blebbing and 
also implicate Rho signaling in these active morpholog-
ical changes. The model system described here should 
facilitate future studies of MLCK, Rho, and other sig-
nal transduction pathways activated during the execu-
tion phase of apoptosis.
 
D
 
ynamic 
 
membrane blebbing, along with chromatin
condensation and DNA laddering are three of the
most commonly used criteria for distinguishing
apoptosis from other physiological processes (Wyllie et al.,
1980). Despite their importance, little is known about mech-
anisms underlying these conserved events. In most systems,
the morphological changes that characterize apoptosis oc-
cur shortly before death during a rapid, evolutionarily con-
served stage of invariant duration known as the execution
phase (Earnshaw, 1995; Jacobson et al., 1997). During the
execution phase, the caspase family of proteases is thought
to be activated and to cleave specific substrates, rapidly
leading to cell death (Chinnaiyan and Dixit, 1996; Nagata,
1997; Nicholson and Thornberry, 1997). The execution
phase of apoptosis has resisted biochemical characteriza-
tion because its onset is markedly asynchronous across a
population of cells (Lazebnik et al., 1995; McCarthy et al.,
1997; Mills et al., 1997; Messam and Pittman, 1998). Thus,
a simple system for synchronizing cells in the execution
phase of apoptosis would prove useful for elucidating key
signal transduction pathways critical for controlling the
biochemical and morphological changes occurring just be-
fore death. Recently, McCarthy et al. (1997) reported that
inhibition of caspases during apoptosis in Rat-1 fibroblasts
resulted in a population of cells that entered into and re-
mained in the execution phase of apoptosis (measured by
membrane blebbing), with the same time-course as dying
cells but without the appearance of other features of apop-
tosis (e.g., DNA laddering and chromatin condensation).
In the present study, a similar model is described that has
allowed us to identify signaling pathways that regulate the
dramatic membrane blebbing occurring during the execu-
tion phase of apoptosis.
The majority of studies examining the formation of
membrane blebs have focused on the role of cytoskeletal
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proteins. Tumor cells lacking actin binding protein (ABP)
 
1
 
bleb extensively under normal conditions (Cunningham
et al., 1992); cleavage of two other proteins that bind actin,
talin and 
 
a
 
-actinin, correlate with peroxide-induced bleb-
bing (Miyoshi et al., 1996), and a fourth actin-binding cy-
toskeletal protein, fodrin, is cleaved by caspases during apop-
tosis (Martin et al., 1995; Cryns et al., 1996; Nath et al.,
1996; Vanags et al., 1996). Numerous studies have focused
directly on the role of actin in these apoptotic membrane
changes. F actin is necessary for blebbing and eventual
“apoptotic body” formation (Cotter et al., 1992), and the
concentration of F actin is correlated with bleb size (Cun-
ningham, 1995). F actin is present at the base of blebs dur-
ing apoptosis (Laster and MacKenzie, 1996; Pitzer et al.,
1996; Vemuri et al., 1996), and several groups have pro-
posed that actin is cleaved by caspases during apoptosis
(Mashima et al., 1995; Kayalar et al., 1996; McCarthy et
al., 1997; see also Song et al., 1997).
Although cytoskeletal proteins including actin seem to
be involved in membrane blebbing during apoptosis, there
is no direct evidence of a role for myosin as the motor be-
hind these morphological changes (however, it is interest-
ing that microinjection of catalytically active myosin light
chain kinase [MLCK] induces membrane blebs; Fishkind
et al., 1991). Through interactions with actin, the myosin
family of motor proteins is involved in many forms of cell
motility. Conventional nonmuscle myosin (myosin II) has
been implicated in such basic cellular processes as cytoki-
nesis, stress fiber pulling, maintenance of the cortical actin
layer, and secretion of vesicles (for reviews see Grebecki,
1994; Maciver, 1996; Mitchison and Cramer, 1996). Myosin
II contractile activity in smooth muscle and nonmuscle cells
is stimulated through phosphorylation of myosin regula-
tory light chain (MLC) on serine 19 by MLCK (Kohama
et al., 1996; Gallagher et al., 1997). This phosphorylation
catalyzes the interaction of the myosin head with actin and
subsequently allows the myosin ATPase to produce sliding
force. Recent studies have shown the phosphorylation
state of MLC also to be regulated by the small G protein,
Rho. Rho is involved in cytoskeletal rearrangement, in-
cluding cell contraction after lysophosphatidic acid or throm-
bin stimulation (Jalink et al., 1994; Tigyi et al., 1996; Geb-
bink et al., 1997), neurite retraction (Jalink et al., 1994;
Tigyi et al., 1996; Gebbink et al., 1997), and actin stress fi-
ber formation (Ridley and Hall, 1992; Chrzanowska-Wod-
nicka and Burridge, 1996). Rho also stimulates Rho kinase
(ROK), which phosphorylates and inactivates MLC phos-
phatase (Noda et al., 1995; Kimura et al., 1996). In addi-
tion, ROK and MLCK phosphorylate MLC on the same
serine residue (Amano et al., 1996), suggesting that ROK,
like MLCK, increases myosin contractile activity.
In this report, we use the caspase inhibitor, z-VAD-
FMK to block cell death late in the apoptotic process after
initiation of blebbing. This results in a dramatically in-
creased proportion of actively blebbing cells after serum re-
moval. In contrast, this dynamic blebbing does not occur in
apoptosis induced by the general kinase inhibitor, stauro-
sporine (STS), suggesting that blebbing may be controlled
by phosphorylation. We used the enriched population of
blebbing cells after serum removal and z-Val-Ala-Asp-fluo-
romethylketone (z-VAD-FMK) treatment to characterize
key phosphorylation events that occur during the execu-
tion phase of apoptosis. Using cellular and biochemical as-
says, we demonstrate essential roles for myosin II and
phosphorylation of MLC in the formation of membrane
blebs, and identify MLCK and Rho as key regulators of ap-
optotic blebbing. Thus, this report describes a model system
for studying biochemical events that occur during the exe-
cution phase of apoptosis, and thus provides the first de-
scription of how MLCK and Rho signal transduction
mechanisms regulate apoptotic membrane blebbing.
 
Materials and Methods
 
Materials
 
z-VAD-FMK was purchased from Kamiya Biomedical Co. (Seattle, WA);
BaF(BOC-Asp-CH
 
2
 
F-OMe) was from Enzyme Systems Products (Liver-
more, CA); KT5926, KN-93, KT5823, H-89, bisindolylmaleimide 1, ML-9,
and ML-7 were from Calbiochem-Novabiochem Corp. (San Diego, CA);
Hoechst 33342 was from Molecular Probes (Eugene, OR); calyculin A was
from Alamone Labs (Jerusalem, Israel); RPMI 1640, DME, and trypsin/
EDTA were obtained from GIBCO BRL (Gaithersburg, MD); horse
serum was from ICN Pharmaceuticals Inc. (Costa Mesa, CA); FCS was
purchased from Hyclone (Logan, UT); rat tail type 1 collagen was from
Collaborative Research, Inc. (Bedford, MA); [
 
32
 
P]orthophosphate was
from Dupont-NEN (Boston, MA); cytochalasin D, nocodazole, taxol,
staurosporine, protein A–Sepharose, and all other chemicals were ob-
tained from Sigma Chemical Co. (St. Louis, MO).
 
Cell Culture
 
The PC6-3 subline of PC12 cells (Pittman et al., 1993) was cultured at 37
 
8
 
C
with 5% CO
 
2
 
 in RPMI 1640 supplemented with 10% horse serum, 5%
FCS, 100 U/ml penicillin, and 100 
 
m
 
g/ml streptomycin. COS-7 cells were
cultured at 37
 
8
 
C with 5% CO
 
2
 
 in DME supplemented with 10% FCS, 100
U/ml penicillin, and 100 
 
m
 
g/ml streptomycin.
To remove serum, cells were trypsinized and washed three times in se-
rum-free medium. Then 30,000 cells were plated per well in a 24-well tis-
sue culture dish in serum-free medium with either 100 
 
m
 
M z-VAD-FMK,
or an equivalent volume of the vehicle, DMSO. Control cells were washed
and plated at the same density in serum-free N2 medium (5 
 
m
 
g/ml insulin,
30 nM selenium, 10 
 
m
 
g/ml transferrin, 20 nM progesterone, 100 
 
m
 
M pu-
trescine, and 1 mg/ml BSA in RPMI 1640; Bottenstein et al., 1980), and
then incubated with or without z-VAD-FMK. N2 medium prevents serum
deprivation–induced cell death for up to 5 or 6 d (unpublished observa-
tions). STS (1 
 
m
 
M), and either 100 
 
m
 
M z-VAD-FMK or DMSO were
added to cells plated in N2 medium. Cell viability was assessed by count-
ing cells in randomly selected fields, in the presence of 0.0625% trypan
blue. All experiments were also performed with the caspase inhibitor,
BaF, with identical results.
The percentage of blebbing cells was determined for cells grown on col-
lagen (50 
 
m
 
g/ml) coated 24-well tissue culture plates. Culturing cells on
collagen provides a sharper distinction between normal wedge-shaped
cells and round blebbing cells. An observer blinded to experimental con-
dition counted all living cells and scored those with obvious membrane
protrusions as blebbing. The effect of 5 
 
m
 
M KN-93, 30 
 
m
 
M H-89, 5 
 
m
 
M
bisindolylmaleimide 1, 5 
 
m
 
M KT-5823, 4 
 
m
 
M KT-5926, 1 
 
m
 
M staurospo-
rine, and 20 or 80 
 
m
 
M ML-9 on blebbing was determined by counting cells
in the same fields before addition of drug, and 1 h after drug treatment.
Six fields were counted per well, three wells per experiment, and experi-
ments were performed three times.
The effects of cytoskeletal disruption on serum-deprived, z-VAD-FMK–
treated cells were assessed by treating cells with cytochalasin D (0.5 
 
m
 
g/ml),
taxol (100 
 
m
 
M), nocodazole (5 
 
m
 
M), and 2,3-butanedione monoxime (BDM;
15 mM). Drugs were added 24 h after serum removal and z-VAD-FMK
administration, and cells were either counted 1 h later or, in the case of
BDM experiments, cells were followed by time-lapse videomicroscopy.
 
1. 
 
Abbreviations used in this paper
 
: ABP, actin binding protein; BDM, 2,3-
butanedione monoxime; MLC, myosin regulatory light chain; MLCK, my-
osin light chain kinase; ROK, Rho kinase; STS, staurosporine; z-VAD-
FMK, z-Val-Ala-Asp-fluoromethylketone. 
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DNA Laddering and Hoechst Staining
 
DNA laddering was performed as described previously (Pittman et al.,
1993). Briefly, cells were either trypsinized or scraped directly into Eppen-
dorf tubes (serum-free and staurosporine samples, respectively). Cell pel-
lets were resuspended in 0.1 M EDTA, 1% SDS, 100 
 
m
 
g/ml proteinase K,
and 0.2 M Tris, pH 8.5, and then incubated at 60
 
8
 
C for 2 h. After addition
of 5 M potassium acetate, lysates were vortexed and placed on ice for 30
min. The supernatant obtained from centrifugation at 14,000 
 
g
 
 for 15 min
was precipitated with ice-cold ethanol, and DNA was electrophoresed.
For Hoechst staining after serum removal or staurosporine treatment,
300,000 cells were plated on collagen-coated, glass bottom 35-mm tissue
culture dishes (Mat-Tek, Ashland, MA). After experimental treatments,
cells were rinsed three times with PBS and then fixed for 15 min in 4%
paraformaldehyde. Cells were rinsed with PBS three times, incubated
with 5 
 
m
 
g/ml Hoechst 33342 in PBS for 15 min, rinsed once with PBS, cov-
erslipped, and then allowed to dry for several hours.
 
Time-Lapse Videomicroscopy
 
Time-lapse videomicroscopy of cells was performed as described previ-
ously (Mills et al., 1995). Briefly, images were obtained with a video camera
(AG-6050; Panasonic, Secaucus, NJ) attached to a Nikon Diaphot inverted
microscope (Garden City, NJ), and recorded on either a JVC (BR-9000U;
Pine Brook, NJ) or a Sony (SVT-5050; Park Ridge, NJ) time-lapse VHS
VCR. Time-lapse images were then time-base corrected and digitized us-
ing Image 1 software (Universal Imaging, Inc., West Chester, PA). Cul-
ture conditions were identical to those in the incubator (5% CO
 
2
 
, 37
 
8
 
C),
and cells could be recorded for at least 5 d without adverse effects. For
time-lapse experiments, 
 
z
 
200,000 cells were plated on 50 
 
m
 
g/ml collagen-
coated, glass bottom 35-mm dishes. For assessment of drug effects, cells
were transferred to the time-lapse chamber, and a field selected, and then
recorded for at least 10 min (usually 30–60 min) before drug was added.
 
Phosphorylation of MLC
 
The procedure used was adapted from that described previously (Ludlo-
wyke et al., 1989). Cells were labeled for 2 h in medium containing 100
 
m
 
Ci/ml [
 
32
 
P]orthophosphate, scraped into ice-cold PBS, and then pelleted
1 min at 12,000 
 
g.
 
 The cell pellet was resuspended in ice-cold lysis buffer:
1% NP-40, 250 mM NaCl, 5 mM EGTA, 0.5 mM PMSF, 1 
 
m
 
g/ml leupep-
tin, 15 mM 
 
b
 
-mercaptoethanol, 100 mM sodium pyrophosphate, 50 mM
NaF, 20 mM Tris, pH 7.9. Lysates were homogenized through a 26-gauge
needle until no longer viscous and then centrifuged at 14,000 
 
g
 
 for 10 min.
Cells lysates were treated with a 1:20 dilution of crude anti–myosin II anti-
body (obtained from Dr. R. Adelstein, National Institutes of Health, Be-
thesda, MD), and immune complexes isolated using protein A–Sepharose.
Immunoprecipitates were then washed once in lysis buffer and once in
PBS. For MLC separation and quantification, the method of Taylor and
Stull (1988) was adapted as follows: immunoprecipitates were resus-
pended in 9 M urea, 2 mM DTT, 22 mM glycine, 20 mM sucrose, 1 mM
EGTA, and 20 mM Tris, pH 8.8, and then heated to 90
 
8
 
C for 5 min. Sam-
ples were electrophoresed on a separating gel containing 10% acrylamide,
40% glycerol, 22 mM glycine, and 20 mM Tris, pH 8.8, after a stacking gel
consisting of 4% acrylamide, 6 M urea, 22 mM glycine and 20 mM Tris,
pH 8.8. Running buffer was 22 mM glycine and 20 mM Tris, pH 8.8. Gels
were pre-electrophoresed for 1 h at 350 V with 1 mM DTT added to the
upper chamber. Then samples were loaded and electrophoresed for 1.5 h
at 450 V. Gels were dried and then exposed to PhosphorImager plates
(Molecular Dynamics, Sunnyvale, CA). Bands were quantitated using Im-
ageQuant software (Molecular Dynamics). 
 
C3 Exoenzyme Experiments
 
The glutathione-S-transferase (GST) fusion protein of 
 
Clostridium botuli-
num
 
 C3 exoenzyme (construct obtained from Dr. A. Alberts, Imperial
Cancer Research Fund, London, UK) was purified on glutathione Sepha-
rose according to the manufacturer’s instructions (Pharmacia Biotech,
Uppsala, Sweden). Preliminary experiments were performed to determine
optimal conditions for treating cells. Concentrations up to 25 
 
m
 
g/ml puri-
fied C3 in the presence or absence of 10 
 
m
 
g/ml lipofectamine as a vehicle
for increasing cellular uptake were tested (Hirao et al., 1996). Concentra-
tions of 10 
 
m
 
g/ml C3 transferase in 10 
 
m
 
g/ml lipofectamine or 25 
 
m
 
g/ml C3
transferase alone had marked biological effects on blebbing within 2 h.
The C3/lipofectamine combination was used routinely in experiments.
Counts of blebbing cells were made before and 2 h after addition of C3
and lipofectamine. Lipofectamine alone had no effect on blebbing.
 
Results
 
Serum Withdrawal and STS Induce
Apoptosis, but Membrane Blebbing Occurs Only After
Serum Withdrawal
 
Both serum removal and STS induce apoptosis in PC12
cells (Fig. 1). In each case, death is characterized by DNA
laddering and chromatin condensation, and can be inhib-
ited by the general inhibitors of caspases, z-VAD-FMK
(Fig. 1) or BaF (data not shown). The time-course of death
is faster in STS-treated cells; however, the most striking
difference between serum deprivation and treatment with
STS is the absence of membrane blebs in cells after treat-
ment with STS, both with (Fig. 2 
 
b
 
) and without z-VAD-
FMK (data not shown). The lack of membrane blebs in
cells treated with STS suggests that the mechanism under-
lying apoptotic membrane blebbing may be a phosphory-
lation event.
An additional striking observation in these initial exper-
iments is the greatly increased percentage of cells dynami-
cally extruding and retracting membrane blebs in serum-
deprived cultures after treatment with z-VAD-FMK (Fig.
2 
 
a
 
), compared to serum-deprived cells in the absence of
z-VAD-FMK (data not shown). To determine the in-
creased number of blebbing cells in serum-deprived,
z-VAD-FMK–treated cultures, cells were counted and
scored for blebbing at time zero and at 24 h (Fig. 3 
 
a
 
). At
time zero, low percentages of cells with blebs are present
in all groups, which probably reflects the normal back-
ground death in these cultures. After 24 h in serum-free
medium without z-VAD-FMK, only 10% of cells are
blebbing, presumably because these cells undergo the
asynchronous death characteristic of apoptosis. Conse-
quently, only a small percentage of these cells are blebbing
at any one time (Fig. 3 
 
a
 
). Control cells maintained for 24 h
in serum-free medium supplemented with N2 components
have a low background death and very few cells are
blebbing (Fig. 3 
 
a
 
). Inhibition of caspases in the absence of
an apoptotic stimulus does not cause blebbing by itself, as
only a small percentage of z-VAD-FMK–treated cells are
blebbing in medium containing N2 components at 24 h
(Fig. 3 
 
a
 
). The small increase in blebbing in the N2
z-VAD-FMK condition compared to N2 alone at 24 h is
consistent with inhibition of normal background death by
z-VAD-FMK. After serum removal and treatment with
z-VAD-FMK, there is a marked, nearly fivefold increase in
the fraction of cells blebbing at 24 h (Fig. 3 
 
a
 
), supporting a
previous report that z-VAD-FMK blocks death after onset
of blebbing (McCarthy et al., 1997). This raised the possi-
bility of using the increased number of cells stopped early
in the execution phase of apoptosis to investigate the
mechanisms underlying dynamic membrane blebbing.
The time-course of entry into blebbing was determined
using long term time-lapse videomicroscopy (Fig. 3 
 
b
 
) of
cultures of PC12 cells after serum removal and z-VAD-
FMK treatment. The number of actively blebbing cells in-
creasing over time seems to reflect normal, asynchronous
entry into the execution phase of apoptosis (McCarthy 
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et al., 1997). The time-course for accumulation of blebbing
cells is similar to that for cell death seen in cells in serum-
free medium such that 
 
z
 
50% of the cells are dead (Fig. 1 
 
a
 
)
or blebbing (Fig. 3 
 
b
 
) by 24 h. A similar asynchronous en-
try into blebbing is seen in serum-deprived, caspase-inhib-
ited COS-7 cells, although the time-course is longer, and
the proportion of blebbing cells is not as large (data not
shown). In both cases, the morphology of blebbing in
z-VAD-FMK–treated, serum-deprived cells is indistin-
guishable from that seen in the execution phase of apopto-
sis, except that, once these cells start to bleb, they continue
to do so for hours to days rather than dying within the hour
as serum-deprived cells without z-VAD-FMK do. Thus,
treatment of apoptotic cultures with caspase inhibitors
causes accumulation of blebbing cells not only in the Rat-1
fibroblast cell line as previously shown (McCarthy et al.,
Figure 1. Characterization of apoptosis after re-
moval of serum or exposure to STS. (a) PC12
cells were plated in either serum free (SF, u) or
control N2 medium (C, e), and plated with (1) or
without 100 mM z-VAD-FMK. Viability was as-
sessed by trypan blue exclusion. Serum removal
from PC12 cells resulted in z50% death by 30 h;
this death was inhibited by 100 mM z-VAD-FMK.
Data represent the mean 6 SEM for three ex-
periments. (b) PC12 cells were subcultured into
N2 medium and 1 mM staurosporine (STS) with
(e) or without (h) 100 mM z-VAD-FMK. Treat-
ment of PC12 cells with 1 mM STS resulted in
z50% death by 6 h; this death was inhibited by
100 mM z-VAD-FMK. Data represent the mean
6 SEM for three experiments. (c) DNA laddering
caused by serum removal (SF) at 24 h, or stauro-
sporine (STS) treatment at 12 h in the absence
(2) or presence (1) of 100 mM z-VAD-FMK.
Control cells (C) were in N2 medium with DMSO
vehicle. 1-kb DNA ladders are shown for reference
to the right of each gel. Note that z-VAD-FMK
prevents DNA laddering. (d) Hoechst staining of
apoptotic nuclei after serum removal (SF) at 24 h
and staurosporine (STS) treatment at 12 h was
prevented by 100 mM z-VAD-FMK (1). Control
cells (CON) were in N2 medium with DMSO ve-
hicle. Arrowheads indicate apoptotic nuclei. Bar,
40 mM.
Figure 2. Dynamic membrane
blebbing is present in cells
treated with z-VAD-FMK
after serum removal, but is
absent in cells treated with
STS and z-VAD-FMK. (a)
Representative field of serum-
free z-VAD-FMK–treated
cells at 24 h. (b) Represen-
tative field of STS- and
z-VAD-FMK–treated cells at
12 h. Note that some cells form
neurite-like projections after
STS treatment. Phase rings
were purposely misaligned
slightly to decrease phase
“halo” and emphasize sur-
face morphology. Bar, 30 mM.
Figure 3. The number of
blebbing cells increase over
time after serum removal in
the presence of z-VAD-FMK.
(a) Blebbing cells were
scored at 0 and 24 h after
serum removal and initiation
of z-VAD-FMK treatment.
The percentage of blebbing
cells was calculated by divid-
ing the number of blebbing
cells by the total number of
living cells per field. At 24 h,
z50% of serum-deprived,
z-VAD-FMK–treated cells
were blebbing (SF 1 z-VAD,
dark striped bars). SF, serum
free; C, control N2 medium
plus DMSO; and C 1 z-VAD
N2 medium plus 100 mM
z-VAD-FMK. Data represent
the mean 6 SEM for three
experiments. (b) The per-
centage of blebbing cells was calculated every 1.5 h from a time-
lapse video recording of a field of cells treated with 100 mM
z-VAD-FMK after removal of serum. The results depicted are
representative of three separate experiments. 
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1997) but also in adrenal-derived PC12 cells, and kidney-
derived COS-7 cells.
MLCK Activity Regulates Apoptotic
Membrane Blebbing
As all other agents used to induce apoptosis in our labora-
tory (e.g., growth factor withdrawal, UV irradiation, H2O2,
ceramide, and menadione) cause membrane blebbing, the
absence of this feature of apoptosis in STS-treated cells
was intriguing. Two hypotheses could explain this observa-
tion: (1) STS initiates apoptosis downstream of blebbing;
or (2) STS initiates apoptosis upstream of blebbing but
prevents blebbing by concomitantly inhibiting a necessary
downstream kinase. To differentiate between these alter-
natives, cultures of PC12 and COS-7 cells were deprived of
serum, and treated with z-VAD-FMK until a substantial
portion of cells were actively blebbing (24 h of serum dep-
rivation for PC12 cells and 48 h for COS-7 cells). Then
STS was added and cells were followed using time-lapse
videomicroscopy. Both PC12 and COS-7 cells stop bleb-
bing within minutes after addition of STS (Fig. 4) but re-
main viable for hours. In other experiments, blebbing of
UV-irradiated PC12 cells was also inhibited by STS treat-
ment (data not shown), suggesting that the effect of STS is
not limited to trophic factor withdrawal induced apoptotic
blebbing.
To determine which kinase(s) STS inhibits to block bleb-
bing, a panel of more specific inhibitors was screened.
PC12 cells, deprived of serum and treated with z-VAD-
FMK for 24 h, were treated for 1 h with either STS,
KT5926 (an inhibitor of MLCK), KN-93 (an inhibitor of
CAMKII), KT5823 (an inhibitor of protein kinase G), bis-
indolylmaleimide 1 (an inhibitor of protein kinase C) or H-89
(an inhibitor of protein kinase A). Only kinase inhibitors
that inhibit MLCK (i.e., STS and KT5926) have a statisti-
cally significant effect on blebbing—STS decreases blebbing
by 89%, and KT5926 by 39% (Fig. 5 a). The PKA inhibi-
tor, H89, induces rapid death of cells at a concentration
similar to that used in other studies (30 mM; Chijiwa et al.,
1990) and has no effect on blebbing at a slightly lower con-
centration (7.5 mM).
In addition to inhibiting MLCK, KT5926 has activity
against CAMKII (Hashimoto et al., 1991). To ensure that
decreased blebbing is the result of MLCK inhibition, ML-9
and ML-7 (MLCK inhibitors that do not inhibit CAMKII)
were used (Saitoh et al., 1986, 1987). ML-9 at 20 mM inhib-
its blebbing of serum-deprived cells treated with either
z-VAD-FMK by 47%, or BaF by 53% within 1 h (Fig. 5 b).
At 80 mM, ML-9 inhibits blebbing in z-VAD-FMK by
99%, and in BaF by 94% within 1 h (Fig. 5 b). At the higher
concentration, ML-9 causes cells to lift off the tissue cul-
ture plate. When ML-9 is used at an intermediate concen-
tration (40 mM), it rapidly inhibits blebbing after serum
removal not only in the presence (Fig. 6 a) of z-VAD-FMK,
but also in the absence (Fig. 6 b) of z-VAD-FMK, without
causing cells to lift off the tissue culture dish. Similar results
were seen with 10 mM ML-7 (data not shown). This sug-
gests that MLCK regulates apoptotic membrane blebbing,
and the morphological changes that occur in serum-deprived,
z-VAD-FMK cells are mechanistically the same as those
seen in dying, serum-deprived cells.
Populations of Blebbing Cells Have Increased Levels of 
MLC Phosphorylation
Results obtained with inhibitors of MLCK implicate regu-
lation of MLC as a critical component of apoptotic bleb-
bing. To demonstrate that phosphorylation of MLC in-
creases in a population enriched for actively blebbing cells,
levels of MLC phosphorylation were directly assessed by
immunoprecipitating 32P-labeled PC12 cells with antibodies
against myosin II. To increase the percentage of actively
Figure 4. Staurosporine in-
hibits apoptotic blebbing in
PC12 and COS-7 cells. Se-
rum removal and z-VAD-
FMK treatment were per-
formed as described in the
legend to Fig. 1. Cells were
recorded for at least 10 min
before addition of 1 mM STS.
(a) Time-lapse images of a
representative field of PC12
cells 24 h after removal of se-
rum and treatment with 100
mM z-VAD-FMK. 5-min in-
tervals are shown before and
after addition of 1 mM STS
(added at time zero). Note
that 10 min after adding STS,
blebbing ceased. (b) Time-
lapse images of a representa-
tive field of COS-7 cells 48 h
after removal of serum and
treatment with 100 mM
z-VAD-FMK. 13-min inter-
vals are shown before and after addition of 1 mM STS (added at
time zero). Approximately 26 min after STS addition, blebbing
ceased. Bars: (a) 25 mM; (b) 50 mM.
Figure 5.  Inhibitors of
MLCK stop apoptotic mem-
brane blebbing. (a) Addition
of either kinase inhibitor (1
mM STS, 4 mM KT-5926, 5
mM KN-93, 5 mM KT-5823,
or 5 mM bisindolylmalei-
mide 1) or equivalent volume
of DMSO 24 h after serum
deprivation and z-VAD-FMK
treatment. Cells were counted
immediately before addition
of kinase inhibitor, and the
same fields counted 1 h after
addition of inhibitor. Percent
inhibition of blebbing was
calculated by comparing the
portion of cells blebbing be-
fore and after treatment.
Data represent the mean 6
SEM for three experiments.
(b) The MLCK inhibitor, ML-9, inhibits blebbing of cells de-
prived of serum and treated with 100 mM z-VAD-FMK or 100
mM BaF (a general caspase inhibitor) in a dose-dependent man-
ner. Cells were counted as above, in the presence of 20 or 80 mM
ML-9. Data represent the mean 6 SEM for three experiments.The Journal of Cell Biology, Volume 140, 1998 632
blebbing cells, PC12 cells in serum-free medium were
treated with z-VAD-FMK for 24 h. Increased MLC phos-
phorylation is observed in these cells, compared to con-
trol, non-blebbing cells (Fig. 7 a). The relatively low signal,
in both control and serum-deprived, z-VAD-FMK–treated
cultures (Fig. 7 a), can be proportionally enhanced by
treatment with the phosphatase inhibitor, calyculin A, for
15 min (Fig. 7 a; Deery and Heath, 1993). Therefore, caly-
culin A–treated cells were used for the remainder of the
immunoprecipitation experiments. In three independent
experiments, three- to fivefold higher levels of MLC phos-
phorylation were seen in cultures enriched for blebbing
cells (i.e., serum-free, z-VAD-FMK–treated) compared to
serum-free cells without z-VAD-FMK. MLC phosphory-
lation in z-VAD-FMK–treated control cells is similar to
phosphorylation levels of serum-deprived or control cells
in the absence of z-VAD-FMK (Fig. 7 b); therefore,
z-VAD-FMK itself has no effect on MLC phosphoryla-
tion. The MLCK inhibitor, ML-9, not only inhibits
blebbing (Figs. 5 and 6), but also decreases MLC phosphor-
ylation (Fig. 7 c).
Involvement of Rho and Cytoskeletal Proteins in 
Membrane Blebbing
Two lines of evidence support a role for the small G pro-
tein Rho in MLC phosphorylation. First, Rho activates
ROK, which phosphorylates MLC on serine 19, the same
residue phosphorylated by MLCK (Amano et al., 1996).
Second, ROK phosphorylates and deactivates a MLC phos-
phatase subunit, causing increased MLC phosphorylation
levels in cells with rapid phosphate turnover (Noda et al.,
1995; Kimura et al., 1996). To test the role of Rho in bleb-
bing, serum-deprived, z-VAD-FMK–treated cells were in-
cubated for 2 h with Clostridium botulinum toxin C3 trans-
ferase, an enzyme that ADP ribosylates and inactivates
Rho (Sekine et al., 1989; Aktories et al., 1990; Paterson et al.,
1990). C3 treatment for 2 h decreases the percentage of
blebbing cells by z60% (Fig. 8). Time-lapse videomicros-
copy shows that overnight treatment with C3 completely
inhibits blebbing without cell loss (data not shown).
Several agents that alter the cytoskeleton, were tested
for immediate effects on blebbing. Incubation of serum-
deprived, z-VAD-FMK–treated cells with nocodazole, a
microtubule destabilizer, modestly increases the already
considerable fraction of blebbing cells (Table I). Taxol, a
microtubule stabilizer, has little effect during the short
time frame of the experiment, whereas cytochalasin D, a
destabilizer of actin filaments, greatly inhibits blebbing
in serum-deprived, z-VAD-FMK–treated cells within an
hour (Table I). Inhibition of myosin ATPase function with
BDM does not affect the number of cells with blebs when
viewed in static cultures (Table I). However, time-lapse
videomicroscopy reveals that BDM dramatically slows the
blebbing process, in fact, cells are often “frozen” with
blebs extended (Table I; see Discussion). Thus, inactiva-
tion of myosin function with BDM appears to inhibit both
protrusion and retraction of blebs.
Discussion
By increasing the fraction of cells undergoing morphologi-
cal changes characteristic of the execution phase of apop-
tosis, we were able to demonstrate that MLCK activity is
critical for dynamic membrane blebbing, and moreover,
that an increased level of myosin II regulatory light chain
phosphorylation is present in enriched populations of
blebbing cells. Our data also implicate the small G protein,
Figure 6. ML-9 inhibits apoptotic blebbing in PC12 cells. (a)
Time-lapse images of a representative field of 24-h serum-
deprived, z-VAD-FMK–treated cells at 4-min intervals before
and after addition of 40 mM ML-9 at time zero. Similar results are
seen with 10 mM ML-7 (data not shown). (b) Time-lapse images
of a field of cells after serum removal in the absence of z-VAD-
FMK before and after addition of 40 mM ML-9 at time zero. Note
the field in b was selected to include several blebbing cells. Due
to asynchrony (see Results, and Fig. 3), only z10% of PC12 cells
after serum removal are blebbing at one time, so it is not typical
to find several blebbing cells in the same field in the absence of
z-VAD-FMK. Bar, 25 mM.
Figure 7. Phosphorylation
of MLC is increased in
blebbing cells and blocked by
ML-9 treatment. Serum re-
moval and z-VAD-FMK treat-
ment were performed as de-
scribed in Fig. 1. 32P-Labeled
cell lysates were immuno-
precipitated with anti–human
platelet myosin II antibody,
electrophoresed on a urea
gel, and then analyzed on a
Molecular Dynamics Phos-
phorImager. (a) Pre-treatment
with 200 nM of the phos-
phatase inhibitor, calyculin A
(CalA), increases MLC phos-
phorylation in both serum
free (SF) and control (C) cells. Cells were pretreated with calyculin
A for the rest of the experiments. A nonspecific rabbit IgG was
used as a control, all other immunoprecipitations were performed
with the anti–human platelet myosin II antibody. (b) Neither se-
rum removal nor z-VAD-FMK alone increase phosphorylation of
myosin light chain; however, cells treated with z-VAD-FMK after
serum removal for 24 h (i.e., blebbing) have increased phosphor-
ylation of MLC. (c) Addition of 40 mM ML-9 to cells deprived of
serum and treated with 100 mM z-VAD-FMK decreases the phos-
phorylation of MLC. The gels in b and c were electrophoresed
longer to visualize the mono- and di-phosphorylated forms of
MLC. Bars shown to the right of image indicate positions of puri-
fied proteins run next to immunoprecipitates on the gel. The es-
sential MLC (E-MLC), and the slower migrating (top) regulatory
MLC (R-MLC) are not phosphorylated. The two lower R-MLC
bands indicate the mono- and di-phosphorylated forms of MLC.Mills et al. Myosin Phosphorylation Regulates Blebbing 633
Rho, in cellular blebbing. Finally, evidence is presented
that several cytoskeletal proteins play an important role in
normal apoptotic blebbing. Thus, we extend the previ-
ously known motile events requiring myosin II by demon-
strating for the first time, an essential role for this key cel-
lular motor in membrane blebbing—a form of cell motility
present not only during apoptosis but also during cell divi-
sion. The model system described here, as well as the
broader implications of MLCK and Rho signaling during
the execution phase should have considerable impact on
future studies characterizing signaling events during the
execution phase of apoptosis.
Apoptosis is a physiological process, defined by charac-
teristic and evolutionarily conserved morphological changes
including DNA laddering, chromatin condensation, mem-
brane blebbing, cell shrinkage, and apoptotic body forma-
tion. Morphological events such as these distinguish apop-
tosis from other cellular processes; therefore, it is likely
that these conserved features of apoptosis are critical as-
pects of the apoptotic process in vivo. Recently, there has
been considerable interest in identifying mechanisms un-
derlying these late processes (McCarthy et al., 1997; Rudel
and Bokoch, 1997); however, the pathways that lead to
these downstream events have been difficult to analyze
biochemically because they occur asynchronously in a
population of cells, with only z10% of cells in the execu-
tion phase at one time (Earnshaw, 1995; Mills et al., 1997;
Messam and Pittman, 1998). Using z-VAD-FMK to inhibit
death and synchronize cells early in the execution phase
(i.e., before DNA laddering and chromatin condensation;
McCarthy et al., 1997) has allowed us to characterize one
of the hallmark features of apoptosis, membrane blebbing.
This system should prove useful for continued character-
ization of regulatory mechanisms involved in blebbing,
and for defining other signaling pathways activated during
the execution phase of apoptosis.
A summary of our data in the context of the execution
phase of apoptosis is provided in Fig. 9. An apoptotic stim-
ulus (such as serum removal) activates several pathways
that lead to a characteristic apoptotic death (i.e., DNA
laddering, chromatin condensation, and membrane bleb-
bing). Using caspase inhibitors to block cell death, a syn-
chronous population of cells “trapped” early in the exe-
cution phase of apoptosis is generated, after initiation of
blebbing, but before other characteristic changes such as
chromatin condensation and DNA laddering (McCarthy
et al., 1997). This system was used to demonstrate that
MLC phosphorylation is crucial for membrane blebbing,
as inhibition of MLCK (with STS, KT5926, ML-9, and
ML-7) decreases blebbing, and phosphorylation of MLC is
markedly enhanced in blebbing cells. Also, the small GTP-
ase, Rho, which increases phosphorylation of MLC, was
shown to be important for apoptotic membrane blebbing,
as Rho inactivation also inhibits blebbing. Therefore, the
Figure 8. The Rho inhibitor C3
transferase decreases blebbing.
10  mg/ml C3 and 10 mg/ml lipo-
fectamine were added to cul-
tures deprived of serum and
treated with z-VAD-FMK for
24 h. Percent blebbing cells was
calculated by dividing the num-
ber of blebbing cells by the number of total cells after 2 h of treat-
ment with either vehicle (DMSO) or C3 transferase (C3). Data
are mean 6 SEM from three independent experiments.
Table I. Immediate Effects on Blebbing
Treatment Response Description
Cytochalasin D
(actin depolymerizer)
¯¯¯ A decrease in blebbing was
seen 10 min after addition of
cytochalasin D, and this
inhibition was seen for the
length of the experiment (1 h).
Taxol
(microtubule stabilizer)
— No change was observed
in blebbing over the
time-course of the
experiment (1 h).
Nocodazole
(microtubule destablizer)
­ No initial changes are apparent
in amount of blebbing cells,
although by 1 h there is an
increase in number of
blebbing cells.
BDM
(inhibits myosin ATPase)
¯¯ No changes are apparent by
counting static cultures.
Observation of cells via
time-lapse however, shows
a striking decrease in the rate
of protrusions and retractions
(cells appear “frozen” in place
with blebs extended).
24 h after serum removal and z-VAD-FMK treatment, either cytochalasin D (0.5 mg/ml),
taxol (100 mM), nocodazole (5 mM), or BDM (15 mM) was added to cultures. 1 h
later, the number of blebbing cells was counted. Time-lapse videomicroscopy was
also used to determine effects of BDM on blebbing.
Figure 9. Signal transduction pathways regulating membrane
blebbing during the execution phase of apoptosis. An apoptotic
stimulus, such as serum removal, triggers pathways leading to
DNA laddering, chromatin condensation, membrane blebbing,
and the eventual death of the cell. Using z-VAD-FMK to inhibit
caspases, cell death is blocked, along with the characteristic fea-
tures, DNA laddering and chromatin condensation (McCarthy et al.,
1997). Apoptotic membrane blebbing still occurs; therefore, bleb-
bing is probably initiated before caspase activation. For blebbing
to occur, the myosin regulatory light chain (MLC) must be phos-
phorylated, as demonstrated by inhibitors of myosin light chain
kinase (MLCK) blocking blebbing and the increased phosphory-
lation state of MLC in serum-deprived, z-VAD-FMK–treated
cells. This phosphorylation can be inhibited by inhibition of
MLCK. Also, the small G protein Rho regulates blebbing, as in-
activation of Rho with C3 transferase inhibits bleb protrusion.
ROK, Rho kinase; MP, myosin phosphatase.The Journal of Cell Biology, Volume 140, 1998 634
data described in this paper provide starting points to be-
gin elucidating upstream and downstream signaling events
from MLCK and Rho during the execution phase of apop-
tosis.
Signal transduction pathways implicated in regulation of
apoptosis such as those involving extracellular signal-regu-
lated kinase 1/2 (Xia et al., 1995; Cuvillier et al., 1996),
stress-activated protein kinases (Johnson et al., 1996; Ver-
heij et al., 1996; Zanke et al., 1996; Ichijo et al., 1997),
phosphotidylinositol-3 kinase (Dudek et al., 1997; Kauff-
mann-Zeh et al., 1997), and AKT/PKB kinase (Dudek et
al., 1997; Kauffmann-Zeh et al., 1997) have been identified;
however, these are activated early in the apoptotic pro-
cess, long before cells enter the execution phase (Park et
al., 1996). Being able to accumulate a large number of syn-
chronized cells late in the apoptotic process allowed us to
demonstrate a critical role for MLC phosphorylation in
maintaining membrane blebbing. Phosphorylation of its
regulatory light chain allows myosin II to bind actin and
ultimately results in force generation for many types of
cell motility. The phosphorylation state of MLC is medi-
ated by MLCK (Kohama et al., 1996), a myosin-specific
phosphatase (Alessi et al., 1992; Hubbard and Cohen,
1993), and ROK. ROK has a dual role, both directly by
phosphorylation and activation of MLC and indirectly by
inhibiting the MLC phosphatase (Noda et al., 1995;
Amano et al., 1996; Kimura et al., 1996). In addition to
regulating MLC phosphorylation, Rho is involved in rear-
rangement of the cytoskeleton, including cell contraction
after lysophosphatidic acid or thrombin stimulation (Ja-
link et al., 1994; Tigyi et al., 1996; Gebbink et al., 1997),
neurite retraction (Jalink et al., 1994; Tigyi et al., 1996;
Gebbink et al., 1997), and actin stress fiber formation
(Ridley and Hall, 1992; Chrzanowska-Wodnicka and Bur-
ridge, 1996). Therefore, the involvement of Rho signaling
in the morphological changes during apoptosis is not sur-
prising.
The involvement of both MLCK and Rho signaling in
the phosphorylation state of MLC may at first seem un-
necessary, but this overlap in function may play an impor-
tant regulatory role. For instance, MLCK could work syn-
ergistically with ROK. In this scenario, MLCK-stimulated
phosphorylation of MLC may be increased by ROK-medi-
ated inhibition of the myosin phosphatase. Here, the pri-
mary effect of ROK is the inhibition of myosin phospha-
tase, and the MLC phosphorylation by ROK may play a
secondary role. Cells may need such a two-pronged ap-
proach on MLC phosphorylation to sustain the uninter-
rupted increase in cellular contractility that characterizes
apoptotic blebbing. Another possibility is that, unlike MLCK
(which requires calcium/calmodulin for activation), ROK
function is not calcium-dependent. Thus, ROK phosphor-
ylation of MLC may provide a calcium-independent mech-
anism for activation of myosin II.
The implication of myosin II in the mechanism of mem-
brane blebbing, allows us to propose a working model of
how early execution phase morphological changes occur in
a cell. It has long been thought that myosin contraction of
the peripheral actin ring produces centripetal force (Gre-
becki, 1994), which acts to compress the cytoplasm in the
center of the cell. If structural proteins (such as ABP and
fodrin) that link the cell membrane to the cortical actin
layer are cleaved, then the centripetal force pushing the
actin ring inward would cause extrusion of the cytoplasm
in areas of weak actin/membrane linkage, resulting in bleb
formation. To support this model for blebbing force pro-
duction, we show that myosin II is necessary for blebbing.
Also supporting the model is the observation in the
present study and in other reports (Keller and Zimmer-
man, 1986; Cotter et al., 1992; Ghibelli et al., 1995) that de-
stabilization of actin filaments with cytochalasin greatly
inhibits blebbing (cytochalasins can induce membrane bub-
bling in some non-apoptotic cells, but the morphological
characteristics of this process are very different from those
of apoptotic blebbing; Prentki et al., 1979, Miranda et al.,
1974). Actin and fodrin are substrates for caspases (Martin
et al., 1995; Cryns et al., 1996; Kayalar et al., 1996; Nath et al.,
1996; Vanags et al., 1996; McCarthy et al., 1997); there-
fore, it has been speculated that caspase activation leading
to actin and fodrin degradation, might lead to blebbing
(Martin et al., 1995; Kayalar et al., 1996). However, data in
this report and that of McCarthy et al. (1997) suggest that
in these systems, blebbing is upstream of caspase inhibi-
tion. If this is true and our proposed working model is cor-
rect, then non-caspase–induced weaknesses in the cortical
actin–membrane linkage must be occurring. Likely agents
to perform this function would be calpains, which are known
to cleave fodrin and other cytoskeletal proteins (Miyoshi
et al., 1996; Nath et al., 1996). Inhibition of calpains pre-
vents cleavage of the cytoskeletal proteins, a-actinin and
talin, and also inhibits hepatocyte blebbing (Miyoshi et al.,
1996). Preliminary data from our lab show that cells do not
bleb if calpain inhibitors are added at the time of z-VAD-
FMK treatment and serum removal (Stone, N.L., unpub-
lished observations), which is consistent with the possibil-
ity that calpains are activated upstream of caspases and
cleave key cytoskeletal proteins.
Destabilization of microtubules also may play an impor-
tant role in the modulation of apoptotic blebbing. Treat-
ment with nocodazole increases blebbing in our system
and in others (Table I; Keller et al., 1985; Keller and Zim-
merman, 1986). Consistent with this observation are stud-
ies showing that microtubules disassemble in the late stages
of apoptosis (Bonfoco et al., 1996; Mills et al., 1998). Addi-
tional studies showing that microtubule disassembly in-
creases cellular contractility (Danowski, 1989; Kolodney
and Elson, 1993), and that this increase in contractility is
mediated by an increase in MLC phosphorylation (Kolod-
ney and Elson, 1995) support our working model of force
generation for membrane blebbing.
Apoptotic membrane blebbing is a combination of dy-
namic protrusion and retraction events. MLCK inhibitors
decrease the fraction of cells with blebs in static cell–
counting experiments and lead to a loss of blebs in time-
lapse videomicroscopy studies. Thus, inhibition of myosin
II activity seems to prevent further protrusion of blebs,
whereas retraction of blebs is not affected by inhibition of
MLCK. However, both protrusion and retraction of blebs
are slowed or stopped by the low affinity inhibitor of the
myosin ATPase, BDM. BDM inhibits unconventional my-
osins as well as myosin II. Therefore, inhibition of bleb re-
traction by BDM suggests that a form of unconventional
myosin may be responsible for retracting blebs. Interest-
ingly, similar observations with BDM and MLCK inhibi-Mills et al. Myosin Phosphorylation Regulates Blebbing 635
tors on growth cone protrusion and retraction have been
observed recently (Ruchhoeff and Harris, 1997).
In addition to regulating blebbing, myosin and Rho ac-
tivity may be involved in mediating other functions during
the execution phase of apoptosis. The first morphological
sign of apoptosis in vivo is a pulling up and away (round-
ing up) from extracellular matrix attachments. Cell con-
traction is mediated by Rho in cells that don’t have strong
adhesions to extracellular matrix, like PC12 cells (Jalink
et al., 1994; Tigyi et al., 1996). In epithelial cell monolayers,
individual apoptotic cells contract, using an actin-dependent
mechanism to pull on neighboring cells (Peralta-Soler et al.,
1996). Because intercellular attachments are maintained,
this contraction performs the important function of auto-
matically closing gaps that would be formed by death of a
cell. Thus, actin-based contraction (likely involving Rho/
myosin regulation) could serve crucial in vivo functions, by
preventing gaps in epithelia or mechanically recruiting neigh-
boring cells to phagocytose apoptotic cells.
This is the first report to define a potential mechanism
for myosin II–mediated force generation during apoptotic
membrane blebbing and to propose a working model of
how blebbing might occur. Synchronizing cells early in the
final phase of apoptosis will facilitate future characteriza-
tion of myosin and Rho in bleb protrusion, as well as pro-
viding a powerful system for studying upstream and down-
stream signaling pathways involved in other conserved
events in the execution phase of apoptosis. Thus, this study
advances our understanding of the signaling events that
occur during apoptosis, and describes the use of a model
system that will allow other features of the execution phase
of apoptosis to be understood mechanistically.
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